Electrolyte Abnormalities
Perioperative electrolyte disturbances reflect renal function, medications, fluid balance, gastrointestinal losses, nutrition and redistribution. Bowel exposed to urine adds a persistent metabolic load. Assess the patient, trend and cause alongside the laboratory result. IV treatment requires the appropriate monitored setting, product concentration and institutional protocol.
See also: Nutrition, ERAS, and Cardiovascular Risk.
Initial Assessment
- Establish symptoms, onset, renal function, urine output, volume status and recent treatments. Review diuretics, renin–angiotensin system drugs, supplements, bowel preparation, insulin, chemotherapy and nutritional intake.
- Repeat an unexpected or potentially unreliable result; do not delay emergency treatment for an unstable patient. Check associated disturbances, particularly magnesium with hypokalemia and calcium during phosphate replacement.
- Select fluid according to volume and acid–base status. Balanced crystalloids are commonly appropriate; saline can aggravate hyperchloremic acidosis and is not a universal intraoperative default.[1]
- Abnormal preoperative potassium is associated with adverse outcomes. Observational studies do not establish that aggressive replacement to a high-normal value prevents those outcomes.[2][3]
Sodium
Hyponatremia
Sodium below 135 mmol/L requires interpretation with glucose, measured osmolality and clinical context. For hypotonic hyponatremia, assess urine osmolality, urine sodium, medications and volume status; consider adrenal insufficiency. Postoperative pain, nausea and antidiuresis can make hypotonic fluid hazardous.[4]
Seizures, coma or other severe neurologic manifestations require urgent monitored 3% saline, using the institution's bolus protocol. The initial objective is a small rise sufficient to reverse cerebral edema, approximately 4–6 mmol/L, followed by controlled correction rather than immediate normalization.[4][5]
For chronic or uncertain-duration hyponatremia, distinguish the correction goal from its upper limit:[5]
- European guidance limits the rise to 10 mmol/L in the first day and 8 mmol/L per day thereafter.
- With high osmotic demyelination risk—especially sodium ≤105 mmol/L, hypokalemia, malnutrition, alcohol use disorder or advanced liver disease—the US/Irish panel recommends no more than 8 mmol/L in any 24 hours, aiming for 4–6.
- Monitor sodium frequently and track urine output. Recovery of water excretion can cause rapid overcorrection even after saline stops. Potassium replacement also contributes to correction.
- If limits are being exceeded, obtain urgent specialist help for measures such as desmopressin and replacement of water losses or sodium relowering.
Subsequent treatment follows the cause: volume replacement for hypovolemia, withdrawal of provoking drugs and usually fluid restriction for SIADH, or management of heart/liver failure for hypervolemic disease. Vaptans and other second-line treatments require specific indications and monitoring.[4]
Hypernatremia
Evaluate water access, losses, osmotic diuresis and diabetes insipidus. Restore circulation first if shock is present, then replace water and ongoing losses with an individualized plan. Duration, neurologic findings and serial sodium measurements guide correction; calculating a water deficit does not replace reassessment.[6]
Potassium
Hypokalemia
Potassium below 3.5 mmol/L is low; ≤2.5 mmol/L, arrhythmia, marked weakness/paralysis or important ECG abnormalities warrant urgent assessment. Investigate gastrointestinal or renal losses, intracellular shifts and magnesium deficiency.[7]
- Prefer oral replacement when the gut functions and urgent IV correction is unnecessary. KCl is particularly useful with chloride depletion; citrate or bicarbonate may suit selected patients with acidosis. Equal milliequivalents of other potassium salts are not intrinsically ineffective.[7]
- Never administer IV potassium as an undiluted injection or IV push. Use a controlled infusion, verify renal function and urine output, and reassess potassium. The cited US KCl label uses a usual ceiling of 10 mEq/hour when potassium is above 2.5 mEq/L; faster rescue regimens require a specific protocol and close monitoring. Product concentration and vascular access also matter.[8]
- Correct magnesium deficiency alongside potassium; do not postpone urgent potassium treatment until magnesium has fully normalized. The rise after a replacement dose varies with continuing losses, redistribution and renal clearance.[7][15]
TIGHT K (2024): routine high-normal replacement is not universally necessary. The trial randomized 1,690 patients undergoing isolated CABG (1,667 in the efficacy analysis). A supplementation trigger of 3.6 rather than 4.5 mEq/L was noninferior for postoperative atrial fibrillation: 27.8% versus 26.2%, risk difference 1.7 percentage points (95% CI −2.6 to 5.9; prespecified noninferiority margin 10 points). This supports reducing unnecessary supplementation in that selected cardiac-surgery population. It does not establish a target for every GU operation, patient with an arrhythmia, or patient with true hypokalemia.[9]
Hyperkalemia
UKKA, updated July 2026: mild 5.5–5.9, moderate 6.0–6.4, severe ≥6.5 mmol/L. Severe hyperkalemia requires emergency treatment. Obtain an ECG at ≥6.0 and use continuous monitoring for severe disease or toxic ECG changes; a normal tracing does not exclude danger.[10]
| Purpose | Treatment |
|---|---|
| Protect the heart with hyperkalemic ECG changes | UKKA uses 30 mL of 10% calcium gluconate over 10 minutes or 10 mL of 10% calcium chloride over 5 minutes. Chloride is preferred in arrest/peri-arrest; gluconate otherwise. Reassess ECG.[10][11] |
| Shift potassium | 10 units soluble insulin with 25 g glucose IV over 15–30 minutes for severe disease. If pretreatment glucose is below 7 mmol/L (126 mg/dL), follow with 10% glucose at 50 mL/hour for 5 hours. Nebulized albuterol/salbutamol 10–20 mg is an adjunct.[10] |
| Remove potassium | Obtain urgent renal/critical-care input for severe or refractory disease; dialysis may be necessary. Binders cannot replace immediate stabilization.[10][12] |
Calcium does not lower potassium. These salts are not interchangeable milliliter-for-milliliter: 10% gluconate contains about one-third the calcium of 10% chloride. Confirm preparation and IV patency.[11]
After insulin, UKKA monitoring: glucose at baseline and 30, 60, 90, 120, 180, 240, 300 and 360 minutes; potassium at 1, 2, 4, 6 and 24 hours. Continue monitoring with repeat treatment. IV bicarbonate is not routine.[10]
US labeling states that sodium zirconium cyclosilicate is not an emergency treatment for life-threatening hyperkalemia because of delayed onset. Adjunctive use must not delay urgent treatment or dialysis.[12]
Calcium
Confirm the Abnormality
Total, albumin-adjusted and ionized calcium are not interchangeable. A 2025 study of 22,658 adults found substantial misclassification with commonly used albumin-adjustment formulas, particularly in hypoalbuminemia. When clinical findings, albumin or acid–base disturbance make total calcium difficult to interpret, measure ionized calcium rather than assuming a correction formula establishes the diagnosis.[13]
Hypocalcemia
Assess magnesium, phosphate, renal function, PTH, vitamin D and relevant drugs. Symptoms include paresthesias, tetany, seizures and QT prolongation.[14]
The Society for Endocrinology uses albumin-adjusted total calcium below 1.9 mmol/L (approximately 7.6 mg/dL), or symptomatic hypocalcemia at any low level, as an emergency threshold, not an ionized-calcium cutoff. Its regimen is 10–20 mL of 10% calcium gluconate in 50–100 mL of 5% dextrose over 10 minutes with ECG monitoring, repeated if needed, followed by a titrated infusion when indicated. This differs from the hyperkalemic membrane-stabilization regimen above.[14]
Stable patients may receive oral calcium and treatment of the cause. Calcitriol is not automatically indicated for every low calcium result: it is used in settings such as hypoparathyroidism, with titration and monitoring. Correct coexisting magnesium deficiency. Thiazides are not routine acute calcium rescue.[14][15]
Hypercalcemia
Confirm calcium status, assess hydration and measure PTH to guide the differential. Consider malignancy, primary hyperparathyroidism and medications; do not assume that prostate cancer with bone metastases explains the result.[16]
- Rehydrate with isotonic saline according to volume status and cardiac/renal reserve, reassessing frequently. Routine forced saline loading plus loop diuretics is inappropriate; loops are mainly reserved for fluid overload.[16]
- For hypercalcemia of malignancy, the Endocrine Society recommends an IV bisphosphonate or denosumab; its conditional preference for denosumab rests on very low-certainty evidence. The guideline does not restrict denosumab to bisphosphonate-refractory disease.[17]
- If total/albumin-adjusted calcium is above 14 mg/dL (3.5 mmol/L), add calcitonin to antiresorptive treatment initially; limit calcitonin to 48–72 hours because of tachyphylaxis. Renal function, vitamin D and hypocalcemia risk affect antiresorptive selection and monitoring. Treat the underlying malignancy.[17]
Magnesium
Hypomagnesemia may accompany hypokalemia and hypocalcemia. Look for gastrointestinal losses, poor intake, renal wasting and drugs such as PPIs, diuretics, calcineurin inhibitors and platinum chemotherapy. Metabolic alkalosis is not universal. Urinary output from an ileal conduit is not equivalent to loss from a gastrointestinal ileostomy.[15]
Use oral magnesium for uncomplicated mild deficiency, adjusting to tolerability; diarrhea can limit replacement. Severe or symptomatic deficiency requires monitored IV magnesium sulfate and repeat measurements. NHS SPS guidance uses 5 g (20 mmol) initially for severe/symptomatic deficiency, ordinarily infused at 1–2 g/hour; institutional regimens vary. This is a replacement regimen, not an arrest/torsades protocol. Individualize dosing in renal impairment and obtain specialist advice for AKI, advanced CKD, dialysis or transplant recipients. Monitor magnesium, potassium, calcium, renal function and blood pressure; use ECG monitoring with severe symptoms.[18]
Treat the underlying cause of persistent deficiency. SGLT2 inhibitors and prebiotics have emerging magnesium-related evidence but are not standard acute replacement. An ileal conduit alone does not establish a need for chronic parenteral magnesium.[15]
Excess magnesium is most concerning when renal clearance is impaired. Stop magnesium sources and urgently assess hypotension, bradycardia, respiratory depression or reduced reflexes; severe toxicity requires critical-care/renal input, with ventilatory support and IV calcium when indicated.[23]
Phosphate
Hypophosphatemia is usually defined as below 2.5 mg/dL (0.8 mmol/L); below 1 mg/dL (0.32 mmol/L) is severe. Investigate refeeding, redistribution, gastrointestinal or renal loss, and medications. Remember phosphate wasting after kidney transplantation and repeated ferric carboxymaltose infusions.[19]
- Severe or symptomatic deficiency—such as respiratory weakness, arrhythmia or rhabdomyolysis—generally warrants IV phosphate in a monitored setting.
- Use a product-specific protocol; choose sodium versus potassium phosphate according to potassium and renal function. Monitor phosphate, calcium and potassium. Avoid rapid infusion and automatic full dosing in renal impairment.
- Oral replacement usually suits stable patients who require supplementation and can absorb it. Divided doses may cause diarrhea. Treat the cause; active vitamin D is not a universal replacement for ordinary vitamin D deficiency.
The 2025 umbrella systematic review found 33 reviews/guidelines/consensus statements and substantial variation in dosing and indications. It excluded ICU settings and does not establish a single validated regimen for all postoperative patients.[19]
Refeeding Syndrome
Use the Nutrition pathway for risk assessment, thiamine, calorie initiation and monitoring. It distinguishes ASPEN and NICE recommendations. Check potassium, magnesium and phosphate before feeding; manage severe deficits and advancing nutrition together. Do not delay emergency glucose for hypoglycemia while arranging thiamine.
GU-Specific Considerations
Bowel Exposed to Urine
| Segment | Characteristic metabolic concern |
|---|---|
| Ileum or colon, including ileocolonic reservoirs | Hyperchloremic metabolic acidosis; potassium depletion can coexist. Risk depends on surface area, contact time and renal reserve. |
| Jejunum, now rarely used | Hyponatremia, hypochloremia, hyperkalemia, dehydration and metabolic acidosis. |
| Stomach, historical/selected reconstruction | Hypochloremic, hypokalemic metabolic alkalosis. |
These patterns guide investigation; not every patient develops every abnormality. Reservoirs generally expose more bowel to urine for longer than short conduits. Correction of acidosis can worsen potassium depletion, so monitor both.[20][21]
Follow renal function, electrolytes/bicarbonate, drainage and upper-tract anatomy long term. Investigate obstruction, infection, dehydration and stones when results deteriorate. EAU recommends annual B12 testing after cystectomy with bowel diversion; neither a fixed ileal length nor a fixed number of postoperative years reliably excludes deficiency.[22]
Individualize alkali treatment to persistent acidosis, potassium, renal function and sodium/volume burden. See Urinary Acidifiers & Alkalinizers and Vitamin B12 Supplementation. Catheterizable reservoirs need their prescribed emptying schedule; changing an external appliance does not empty an obstructed urinary conduit.
Perioperative Application
After major reconstruction, assess ongoing losses, renal function, medications and nutrition before repeated replacement. There is no validated universal instruction to push every cystectomy patient's potassium above 4.0 mmol/L or normalize every mild laboratory deviation before surgery.
Classic dilutional TURP syndrome follows absorption of electrolyte-free irrigation during monopolar resection. Bipolar TURP and HoLEP use saline, reducing that mechanism; substantial saline absorption can still cause volume overload and acid–base disturbance.
References
1. Lorente JV, et al. Perioperative fluid therapy in adults and children: a narrative review. Front Med. 2025. doi:10.3389/fmed.2025.1607670.
2. Wahr JA, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. JAMA. 1999. doi:10.1001/jama.281.23.2203.
3. Arora P, et al. Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery. Clin Chem Lab Med. 2017. doi:10.1515/cclm-2016-0038.
4. Adrogué HJ, Tucker BM, Madias NE. Diagnosis and management of hyponatremia: a review. JAMA. 2022. doi:10.1001/jama.2022.11176.
5. Sterns RH, et al. Treatment guidelines for hyponatremia: stay the course. Clin J Am Soc Nephrol. 2024. doi:10.2215/CJN.0000000000000244.
6. Miller NE, Rushlow D, Stacey SK. Diagnosis and management of sodium disorders: hyponatremia and hypernatremia. Am Fam Physician. 2023;108:476–486. Article.
7. Kim MJ, Valerio C, Knobloch GK. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician. 2023;107:59–70. Article.
8. DailyMed. Potassium chloride injection: prescribing information.
9. O'Brien B, et al. Potassium supplementation and prevention of atrial fibrillation after cardiac surgery: the TIGHT K randomized clinical trial. JAMA. 2024. doi:10.1001/jama.2024.17888.
10. UK Kidney Association. Management of hyperkalaemia in adults. Updated July 2026; hospital recommendations and Appendix 7.
11. MHRA. Potential risk of underdosing with calcium gluconate in severe hyperkalaemia. 2023.
12. DailyMed. Lokelma: prescribing information.
13. Desgagnés N, et al. Use of albumin-adjusted calcium measurements in clinical practice. JAMA Netw Open. 2025. doi:10.1001/jamanetworkopen.2024.55251.
14. Turner J, Gittoes N, Selby P, Society for Endocrinology Clinical Committee. Emergency management of acute hypocalcaemia in adult patients. Endocr Connect. 2016. doi:10.1530/EC-16-0056; 2019 calcium-preparation addendum.
15. Kröse JL, de Baaij JHF. Magnesium biology. Nephrol Dial Transplant. 2024. doi:10.1093/ndt/gfae134.
16. Walsh J, Gittoes N, Selby P, Society for Endocrinology Clinical Committee. Emergency management of acute hypercalcaemia in adult patients. Endocr Connect. 2016. doi:10.1530/EC-16-0055.
17. El-Hajj Fuleihan G, et al. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023. doi:10.1210/clinem/dgac621; recommendations.
18. NHS Specialist Pharmacy Service. Treating acute hypomagnesaemia in adults. 2024.
19. Netzer S, Büchel L, Büchi AE, Aubert CE. Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines. BMC Med. 2025;23:591. doi:10.1186/s12916-025-04415-1.
20. Vasdev N, Moon A, Thorpe AC. Metabolic complications of urinary intestinal diversion. Indian J Urol. 2013. doi:10.4103/0970-1591.120112.
21. Stein R, Rubenwolf P. Metabolic consequences after urinary diversion. Front Pediatr. 2014. doi:10.3389/fped.2014.00015.
22. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Follow-up: functional outcomes and complications. 2026.
23. DailyMed. Magnesium sulfate injection: precautions and overdose management.